Why the study?
Irreversible loss of functional cardiomyocytes causes significant ongoing morbidity after acute myocardial infarction, with inflammation recognized as a key mediator of postinfarction adverse ventricular remodeling.
Does mesenchymal stem cell therapy limit secondary injury and promote myocardial healing after myocardial infarction?
Does mesenchymal stem cell therapy limit secondary injury and promote myocardial healing after myocardial infarction?
Mesenchymal stem cells may serve as potential immunomodulators to limit secondary injury and promote healing after myocardial infarction.
MSC therapy should not yet change post-MI practice; leaves open its immunomodulatory role in limiting secondary injury.
Ischemic heart disease is a growing worldwide epidemic. Improvements in medical and surgical therapies have reduced early mortality after acute myocardial infarction and increased the number of patients living with chronic heart failure. The irreversible loss of functional cardiomyocytes puts these patients at significant risk of ongoing morbidity and mortality after their index event. Recent evidence suggests that inflammation is a key mediator of postinfarction adverse remodeling in the heart. In this review, we discuss the cardioprotective and deleterious effects of inflammation and its mediators during acute myocardial infarction. We also explore the role of mesenchymal stem cell therapy to limit secondary injury and promote myocardial healing after myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: